Skip NavigationSkip to Content
Return Return to Search Results

Oral recombinant methioninase combined with oxaliplatinum and 5-fluorouracil regressed a colon cancer growing on the peritoneal surface in a patient-derived orthotopic xenograft mouse model

  1. Author:
    Park, Jun Ho
    Han, Qinghong
    Zhao, Ming
    Tan, Yuying
    Higuchi, Takashi
    Yoon, Sang Nam
    Sugisawa, Norihiko
    Yamamoto, Jun
    Bouvet, Michael
    Clary, Bryan
    Singh,Shree Ram
    Hoffman, Robert M

  2. Author Address

    AntiCancer Inc., San Diego, CA, USA; Department of Surgery, Kangdong Sacred Heart Hospital, Hallym University College of Medicine, Seoul, South Korea; Department of Surgery, University of California, San Diego, CA, USA., AntiCancer Inc., San Diego, CA, USA., AntiCancer Inc., San Diego, CA, USA; Department of Surgery, University of California, San Diego, CA, USA., Basic Research Laboratory, National Cancer Institute, Frederick, MD, USA. Electronic address: singhshr@mail.nih.gov., AntiCancer Inc., San Diego, CA, USA; Department of Surgery, University of California, San Diego, CA, USA. Electronic address: all@anticancer.com.,
    1. Year: 2019
    2. Date: Dec
    3. Epub Date: 2019 09 21
  2. Journal: Tissue & cell
    1. 61
    2. Pages: 109-114
  4. Type of Article: Article
  5. ISSN: 0040-8166
  1. Abstract:

    The aim of this study was to determine the efficacy of oral recombinant methioninase (o-rMETase) on a model of colon cancer growing on the peritoneal surface using a patients-derived orthotopic xenograft (PDOX) nude mouse model. Forty PDOX mouse models with colon cancer growing on the peritoneum were divided into 4 groups of 10 mice each by measuring the tumor size and fluorescence intensity: untreated control; 5-fluorouracil (5-FU) (50 mg/kg, once a week for two weeks, ip) and oxaliplatinum (OXA) (6 mg/kg, once a week for two weeks, ip); o-rMETase (100 units/day, oral 14 consecutive days); combination 5-FU + OXA and o-rMETase. All treatments inhibited tumor growth compared to the untreated control. The combination of 5-FU + OXA plus o-rMETase was significantly more efficacious than the control and each drug alone and was the only treatment that caused tumor regression. The present study is the first demonstrating the efficacy of o-rMETase combination therapy on a PDOX model of peritoneal colon cancer, suggesting potential clinical development of o-rMETase in a recalcitrant cancer.

    See More

  1. Keywords:

External Sources

  1. View Full Text
  2. DOI: 10.1016/j.tice.2019.09.006
  3. PMID: 31759402
  4. View record in Web of Science®
  5. WOS: 000497983800014
  6. PII : S0040-8166(19)30246-0

Library Notes

  1. Fiscal Year: FY2019-2020
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel